What happened
In a draft report, the Institute for Clinical and Economic Review said AstraZeneca’s newly approved hypertension drug Baxfendy does not meet traditional cost-effectiveness standards at its current price. ICER used a wholesale acquisition cost of $900 for 30 tablets, or $10,800 annually before discounts and rebates. At that price, the group concluded that Baxfendy was too expensive relative to its assessed benefit.
ICER used the same price as a placeholder for Mineralys Therapeutics’ investigational aldosterone synthase inhibitor lorundrostat, which is up for an FDA decision in December, and reached the same conclusion there. The group wrote that the health benefits of baxdrostat or lorundrostat are “promising but inconclusive” versus generic blood pressure medicines including spironolactone, eplerenone and amiloride. It also said it could not determine from its analysis whether one agent has superior blood pressure lowering over the other. Baxfendy was approved by the FDA in May to be used with other antihypertensive therapies in patients whose high blood pressure can’t be adequately controlled.
Why it matters
For payers, this is the familiar early warning shot before coverage policy hardens. ICER is not a regulator. Still, a draft finding that a new therapy sits well above commonly used cost-effectiveness thresholds can become a practical negotiating anchor, especially when the comparator set includes low-cost generics and when ICER itself says the long-term effects of aldosterone synthase inhibitors, plus efficacy and safety in subgroups such as patients with chronic kidney disease, still need more clarity.
The immediate implication is not that Baxfendy won’t be covered, but that access could tighten around the labeled population and around patients already on multiple antihypertensive medicines. For more on PBM economics, see RxPBM.ai.
The broader read-through is for the class, not just AstraZeneca. ICER applied the same placeholder price to lorundrostat and landed in the same place, leaving Mineralys to approach its December FDA decision with a reimbursement debate already framed. AstraZeneca’s response leaned on unmet need and called Baxfendy “the first new innovation in hypertension management in more than two decades.” The source notes that the approval was backed by a phase 3 trial showing statistically significant and clinically meaningful blood pressure reductions in patients already taking two or more hypertension medicines.
Even so, investors should watch whether future evidence closes the gap ICER highlighted between blood pressure lowering and harder long-term value claims. For detailed drug monographs, see ClinicalRx.ai.
